Roche’s Polivy Set For Blockbuster Sales After Frontline Lymphoma Success
First Progress In Frontline DLBCL In 20 Years
Roche has not disclosed the full data yet, but is confident that Polivy can surpass CAR-Ts and other competitors to be the new standard of care.
You may also be interested in...
Roche presents further analysis on Tecentriq’s potential first-in-class adjuvant use, which could add up to $3bn a year to revenues.
With big oncology losses largely in the rearview mirror, Roche is trying to sell investors on its next wave of cancer drugs; R&D overview pushes message of pipeline renewal.
In this week's podcast edition of Five Must-Know Things: a history of Alzheimer’s drug development; BioNTech looks beyond COVID-19 vaccines; gene therapy setbacks for bluebird; new promise for Roche’s Polivy in B-cell lymphoma; and rising US momentum for US drug price negotiations.